Human Pegivirus Identified in Encephalitis Patients
|
By LabMedica International staff writers Posted on 17 Oct 2018 |

Image: The MiSeq Sequencing platform (Photo courtesy of Illumina).
Human pegivirus (HPgV), was previously called hepatitis G virus or GB virus C, and is a lymphotropic virus with undefined pathology and many viruses from the family Flaviviridae, to which HPgV belongs, are neurotropic.
Infection with HPgV is common worldwide; about 5% of healthy blood donors in industrialized countries are viremic, whereas in some developing countries the prevalence of viremia among blood donors is approximately 20%. There is evidence that HPgV is transmitted parenterally, sexually, and also vertically from mother to child. However, the high proportion of HPgV infection in apparently healthy blood donors and the general population suggests existence of nonparenteral routes.
Scientists from the Medical University of Warsaw (Warsaw, Poland) and their colleagues prospectively enrolled 96 patients with encephalitis at the Warsaw Hospital for Infectious Diseases (Warsaw, Poland) from June 2012 through July 2015. They collected cerebrospinal fluid (CSF) and serum samples from patients at admission (5 to 7 days after symptom onset).
They tested the samples from all 96 patients for the presence of 5′ untranslated region (UTR) HPgV RNA. The team performed real-time quantitative PCR (qPCR) or real-time quantitative reverse transcription PCR (qRT-PCR) to detect other viruses. They detected autoantibodies against neuronal surface antigens using the Autoimmune Encephalitis Mosaic 6 assay. They subjected the amplified PCR products to single-strand conformational polymorphism analysis. The reamplified RT-PCR products with primers specifically designed for the Illumina MiSeq platform.
The scientists found HPgV in serum and cerebrospinal fluid from three patients who had encephalitis of unclear origin; that is, all the markers that had been tested were negative. Single-strand confirmation polymorphism and next-generation sequencing analysis revealed differences between the serum and cerebrospinal fluid–derived viral sequences, which is compatible with the presence of a separate HPgV compartment in the central nervous system.
The authors concluded that they had detected HPgV sequences in the CSF of three patients with encephalitis of unclear origin, and these sequences from CSF differed from those circulating in serum. These findings are compatible with the presence of a separate viral compartment in the CNS. Determining if the pegivirus was responsible for encephalitis or if it was present along with another cause of encephalitis will require further studies including histopathological analysis. The study was published in the October 2018 issue of the journal Emerging Infectious Diseases.
Related Links:
Medical University of Warsaw
Warsaw Hospital for Infectious Diseases
Infection with HPgV is common worldwide; about 5% of healthy blood donors in industrialized countries are viremic, whereas in some developing countries the prevalence of viremia among blood donors is approximately 20%. There is evidence that HPgV is transmitted parenterally, sexually, and also vertically from mother to child. However, the high proportion of HPgV infection in apparently healthy blood donors and the general population suggests existence of nonparenteral routes.
Scientists from the Medical University of Warsaw (Warsaw, Poland) and their colleagues prospectively enrolled 96 patients with encephalitis at the Warsaw Hospital for Infectious Diseases (Warsaw, Poland) from June 2012 through July 2015. They collected cerebrospinal fluid (CSF) and serum samples from patients at admission (5 to 7 days after symptom onset).
They tested the samples from all 96 patients for the presence of 5′ untranslated region (UTR) HPgV RNA. The team performed real-time quantitative PCR (qPCR) or real-time quantitative reverse transcription PCR (qRT-PCR) to detect other viruses. They detected autoantibodies against neuronal surface antigens using the Autoimmune Encephalitis Mosaic 6 assay. They subjected the amplified PCR products to single-strand conformational polymorphism analysis. The reamplified RT-PCR products with primers specifically designed for the Illumina MiSeq platform.
The scientists found HPgV in serum and cerebrospinal fluid from three patients who had encephalitis of unclear origin; that is, all the markers that had been tested were negative. Single-strand confirmation polymorphism and next-generation sequencing analysis revealed differences between the serum and cerebrospinal fluid–derived viral sequences, which is compatible with the presence of a separate HPgV compartment in the central nervous system.
The authors concluded that they had detected HPgV sequences in the CSF of three patients with encephalitis of unclear origin, and these sequences from CSF differed from those circulating in serum. These findings are compatible with the presence of a separate viral compartment in the CNS. Determining if the pegivirus was responsible for encephalitis or if it was present along with another cause of encephalitis will require further studies including histopathological analysis. The study was published in the October 2018 issue of the journal Emerging Infectious Diseases.
Related Links:
Medical University of Warsaw
Warsaw Hospital for Infectious Diseases
Latest Molecular Diagnostics News
- Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
- Blood Test Enables Early Detection and Classification of Glioma
- Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
- New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
- Framework Guides Targeted Immunotherapy Selection in Liver Cancer
- Collaboration Brings Rapid At-Home STI Testing with Virtual Follow-Up
- Blood-Based Epigenetic Signals Enable Osteosarcoma Disease Monitoring
- Host–Virus Genetic Interactions Drive Nasopharyngeal Cancer Risk
- AI-Enabled Biochip Detects microRNA Biomarkers in Minutes
- Blood Test Detects Early Pancreatic Cancer in High-Risk Patients
- Long-Read RNA Sequencing Platform Improves Rare Disease Diagnosis
- Study Confirms Barrett’s Esophagus as Precursor to Esophageal Cancer
- Ultrasensitive Assay Reveals Previously Undetected Tuberculosis in Hospital Patients
- CE-Marked Blood Test Enables Monitoring of Neuroinflammation in Multiple Sclerosis
- Urine-Based Assay Predicts Severe Dengue Risk Early
- Ultrasensitive Assay Tracks Resistance Mutations MRD Monitoring
Channels
Clinical Chemistry
view channel
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more
Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read moreMolecular Diagnostics
view channel
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Blood Test Enables Early Detection and Classification of Glioma
High-grade gliomas, particularly glioblastoma, are fast-growing brain tumors that are often diagnosed late and typically require invasive procedures for confirmation. Current pathways rely on symptoms,... Read more
Multi-Biomarker Blood Test Detects Early-Stage Cancers Across Types
Abbott is showcasing its Cancerguard multi-cancer early detection (MCED) test at the American Association for Cancer Research (AACR) Annual Meeting 2026, where new data highlight continued progress in... Read more
New Sample-to-Answer PCR System Supports High-Throughput Infectious Disease Testing
Clinical laboratories face mounting demand for rapid, high‑volume molecular testing for infectious diseases, including routine monitoring in immunocompromised patients. Consolidated, sample‑to‑answer workflows... Read moreHematology
view channel
Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
Anemia detected in routine care can signal underlying pathology and is frequently encountered in adults. Because it is defined by hemoglobin levels below the normal range, it is often evaluated with red... Read more
Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
Chronic myelomonocytic leukemia (CMML) is a rare blood cancer in which acquired genetic mutations in bone marrow stem cells drive disease. Stem cell transplantation is the only curative option but carries... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read morePathology
view channel
AI Precision Tests Deliver Cancer Risk Insights from Routine H&E Slides
Reliable prognostic profiling and biomarker screening are essential to guide oncology treatment decisions, while laboratories must balance speed and resource constraints. Earlier identification of high‑risk... Read more
Study Reveals Moleclar Mechanism Driving Aggressive Skin Cancer
Cutaneous squamous cell carcinoma (cSCC) is the world’s second most common skin cancer, and while many cases are treatable, a subset becomes highly aggressive and therapy‑resistant. Identifying molecular... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







